AYTU Aytu BioPharma, Inc.
USHealthcareAs of 2026-07-10 16:00
Why AYTU matters now
Aytu BioPharma, Inc. (AYTU) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.25 with +2.27% on the session and $18.2M in market capitalization; recent performance reads 1-month +11.06% and YTD -11.15%.
The latest financial table shown here is Q3 2026, with revenue of $12.4M, net income of $-5.6M, and EPS of $-0.53. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 8.8%.
The latest indexable market news headline is "Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026" from Accesswire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.69
P/S
0.33
EV/EBITDA
-0.55
DCF Value
$-20.85
FCF Yield
8.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.5%
Operating Margin
-26.8%
Net Margin
-60.2%
ROE
-148.9%
ROA
-30.5%
ROIC
-23.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $12.4M | $-5.6M | $-0.53 |
| Q2 2026 | $15.2M | $-10.6M | $-1.05 |
| Q1 2026 | $13.9M | $2.0M | $-0.08 |
| Q4 2025 | $15.1M | $-19.8M | $-2.92 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.25
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.